MentalHealth_Header

Mental Health DNA Insight®

Help Predict a Patient’s Response to Medications

UNDERSTANDING PHARMACOGENOMICS AND MEDICATION RESPONSE

Many FDA-approved medications are available on the market today to treat a variety of mental health conditions. However, not everyone responds to medications in the exact same way due to factors such as age, weight, general health and nutrition. In addition, an individual’s genetic makeup has been consistently shown to influence how he/she will respond to certain medications. The study of how genetics can affect drug response is known as pharmacogenomics.

MagnifyingGlass_infoGraphic

OUR TEST CAN HELP

Mental Health DNA Insight® analyzes patients’ DNA to identify specific genetic variants that can affect how they respond to over 50 psychiatric medications [see tab below] indicated for major depressive disorder (MDD), schizophrenia, bipolar disorder, epilepsy, seizures, attention deficit/hyperactivity disorder (ADHD), anxiety and other neurological disorders.

MentalHealth_HowItBenefits_infographic

CLINICAL IMPLEMENTATION FOR PATIENTS

Mental Health DNA Insight® can help physicians prescribe more appropriate medications and guide dosage adjustments if necessary. This test can also help avoid potentially severe side effects or understand and avoid a lack of drug efficacy in some patients.

LEARN MORE ABOUT MENTAL HEALTH DNA INSIGHT®

SSRI Antidepressants

Genes Analyzed:

CYP2D6, CYP3A4, SLC6A4, CYP2C19, HTR2A

Drug Class Description:58

Selective serotonin reuptake inhibitors (SSRIs) are prescribed to treat various psychiatric conditions, including depression, anxiety and personality disorders. SSRIs act by blocking the serotonin (5-HT) receptors in the brain1. Suboptimal responses can delay the use of effective medications and remission of symptoms2. Genetic differences can play an important role in determining patient responses3.

SNRI Antidepressants

Genes Analyzed:

CYP2D6, CYP3A4, CYP2B6, SLC6A4

Drug Class Description:58

Serotonin and norepinephrine reuptake inhibitors (SNRIs) such as duloxetine, levomilnacipran and venlafaxine are primarily indicated for the treatment of major depressive disorder (MDD)4-7. Some SNRIs are also prescribed to treat anxiety disorders and neuropathic pain. SNRIs, like SSRIs, are second-generation antidepressants that are better tolerated than first-generation antidepressants such as tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs)8.

TCA Antidepressants

Genes Analyzed:

CYP2D6, CYP2C19

Drug Class Description:58

Tricyclic antidepressants (TCAs) are prescribed to treat depression and various other psychiatric conditions9. TCAs act by blocking the neuronal uptake of norepinephrine and serotonin10; the binding of TCAs to cholinergic, alpha-adrenergic, serotonin and histamine receptors contributes to various side effects.

Other Antidepressants

Genes Analyzed:

CYP2D6, CYP3A4, CYP2B6, SLC6A4

Drug Class Description:58

Other antidepressants that are used to treat depression and anxiety disorders include: Bupropion - a norepinephrine and dopamine reuptake inhibitor (NDRI) and a non-competitive antagonist of the nicotine receptors11, 12; Buspirone – an anti-anxiety medication unrelated to benzodiazepines13; Mirtazapine - a commonly prescribed second-generation tetracyclic antidepressant that inhibits adrenergic alpha2-autoreceptors and serotonin 5-HT2 and 5-HT3 receptors14, 15; nefazodone - a phenylpiperazine antidepressant not related to SSRIs, TCAs and monoamine oxidase inhibitors, and blocks the serotonin 5-HT2 receptors16, 17; trazodone - a serotonin antagonist and a serotonin reuptake inhibitor (SARI) related to nefazodone18, 19; vortioxetine - a multimodal antidepressant that can be a useful alternative to serotonergic antidepressants for some patients who are partial responders or non-responders20, 21.

ADHD Medication (NE reuptake inhibitor)

Genes Analyzed:

CYP2D6

Drug Class Description:58

Atomoxetine is indicated for the treatment of attention deficit/hyperactivity disorder (ADHD) among children, adolescents and adults. It is a potent and selective inhibitor of the pre-synaptic norepinephrine transporter with minor affinity for serotonin and dopamine transporters29.

Benzodiazepines

Genes Analyzed:

CYP2C19, CYP3A5

Drug Class Description:58

Benzodiazepines (BDZ) are a class of drugs primarily used for treating seizures, but they also are effective in treating epilepsy, panic disorders and various other disorders30. The exact mechanism of action of BDZs is not known, but they appear to work by affecting neurotransmitters like gamma-aminobutryic acid (GABA) in the brain.

Mood Stabilizers

Genes Analyzed:

HLA-A, HLA-B, UGT1A4, POLG, CYP2C9

Drug Class Description:58

Carbamazepine, divalproex, lamotrigine, oxcarbazepine, phenytoin and valproic acid are used to treat epilepsy, mania/bipolar disorder and neuropathic pain31-36. The most serious side effects associated with carbamazepine, lamotrigine, oxcarbazepine and phenytoin are blistering skin reactions known as Stevens Johnson syndrome (SJS) and toxic epidermal necrolysis19 37, 38. Other mood stabilizers such as valproic acid and divalproex can increase the risk of liver damage and resultant death in patients with hereditary neurometabolic disorder caused due to inherited POLG mutations35, 39-41.

Typical Antipsychotics

Genes Analyzed:

CYP2D6, CYP1A2, HTR2C, DRD2

Drug Class Description:58-59

Typical antipsychotics (TAPs), also known as first generation antipsychotics, are prescribed to treat various psychiatric disorders, including schizophrenia, mania, agitated behavior and severe anxiety42, 43. This class of drugs acts by blocking dopamine D1 and D2 receptors44-47.

Atypical Antipsychotics

Genes Analyzed:

CYP2D6,

Drug Class Description:58

Atypical antipsychotics are prescribed to treat various psychiatric disorders, including schizophrenia, schizoaffective disorder and bipolar mania48, 49. These medications bind serotonin and dopamine receptors50-55. Stimulation of serotonin receptor 2C (5-HT2C, 5-HTR2C, HTR1C) results in secretion of pro-opiomelanocortin (POMC), enhanced satiety and decreased food intake; therefore, serotonergic agents can decrease food intake and promote weight loss56, 57. Indeed, one of the major side-effects associated with atypical antipsychotics is significant weight gain57.

Other Neurological Medications

Genes Analyzed:

CYP2D6

Drug Class Description:58

Dextromethorphan and quinidine sulfate combination is an oral formulation used to treat pseudo bulbar effect. Galantamine is a cholinesterase inhibitor indicated for the treatment of mild to moderate Alzheimer’s disease22-25. Modafinil is a wakefulness-promoting agent used to treat excessive daytime sleepiness associated with narcolepsy26. Modafinil is often used in combination with tricyclic antidepressant medication27. Tetrabenazine is a vesicular monoamine transporter 2 (VMAT) inhibitor indicated for the treatment of chorea associated with Huntington’s disease28.

Step 1:

Mental Health DNA Insight® can be ordered from a licensed and registered physician or other qualified healthcare provider.

Step 2:

The patient will provide a saliva or blood sample using the collection kit in the Pathway Genomics box.

Step 3:

The authorized physician will mail the sample back to Pathway Genomics, along with the test requisition and consent form (return shipping provided).  View the saliva collection instructional video here.  For blood collection instructions, click here.

Step 4:

Pathway Genomics processes and analyzes the submitted sample in its CLIA certified and CAP accredited laboratory. Typically within two to three weeks, the patient’s personalized results will be available to the ordering physician. The results will then be released to the patient. Pathway Genomics has a team of genetic counselors available to ensure that both the patient and the physician understand the information in the report, and to answer additional questions. To contact a Pathway Genomics genetic counselor, please call client services department at 877-505-7374 or email clientservices@pathway.com.

Mental Health DNA Insight® is best suited for individuals who are about to start one of the indicated psychiatric medications, as well as for patients who are currently taking these medications but are not getting the optimal therapeutic response or are experiencing side effects. This clinically-actionable genetic test can help physicians guide patients’ prescriptions, adjust dosages, and avoid or monitor medications that may have potential adverse effects.

samples_2-3Weeks-MedResponse_White

HOW IT WORKS

This simple saliva- or blood-based test is supported by scientifically validated genetic testing technologies, using clinically relevant markers and assays. In just 2-3 weeks, the Mental Health DNA Insight® report will be delivered to the physicians.

The results of this test are shown in an
easy-to-read, color-coded comprehensive report.

REPORTS – A SIMPLE GUIDE TO UNDERSTANDING

The green category indicates that the drug can be prescribed and used according to the FDA-approved drug label.

The orange category signals caution. For medications in this category, the outcome may indicate that dosing levels need to be lowered or increased, or that the drug’s side effects may cause an adverse reaction for this patient.

The red category indicates that the drug should be used with caution and with more frequent monitoring due to the potential risk of a severe adverse reaction or lack of therapeutic response. Alternative medications are strongly recommended.

GET THE PATHWAY GENOMICS APP TODAY!

  • Access an interactive version of your report anytime, anywhere

  • Learn about other Pathway tests and how they can help you lead a healthier life

  • Help your friends and family by sharing the power of genetic insight

PG-App_Mobile-phone-tablet_wSh

REFERENCES

  1. Vaswani, M., F.K. Linda, and S. Ramesh, Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry, 2003. 27(1): p. 85-102.
  2. Kato, M., et al., Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology, 2006. 53(4): p. 186-95.
  3. Miguita, K., et al., Association study between genetic monoaminergic polymorphisms and OCD response to clomipramine treatment. Arq Neuropsiquiatr, 2011. 69(2B): p. 283-7.
  4. Venlafaxine [package insert] Osmotica Pharmaceutical Corp. Wilmington, NC. July 2014 [cited 2015 November 03]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022104s010lbl.pdf.
  5. Levomilnacipran (Fetzima) [package insert]. Forest pharmaceuticals Inc. St. Louis, MO. July 2013 [cited 2105 November 03]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204168s000lbl.pdf.
  6. Duloxetine (Cymbalta) [package insert]. Lilly USA, LLC, Indianapolis, IN. October 2014 [cited 2015 November 03]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021427s046lbl.pdf.
  7. Knadler, M.P., et al., Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet, 2011. 50(5): p. 281-94.
  8. Spina, E., V. Santoro, and C. D’Arrigo, Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther, 2008. 30(7): p. 1206-27.
  9. Rudorfer, M.V. and W.Z. Potter, Metabolism of tricyclic antidepressants. Cell Mol Neurobiol, 1999. 19(3): p. 373-409.
  10. Hicks, J.K., et al., Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther, 2013. 93(5): p. 402-8.
  11. Stahl, S.M., et al., A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. Prim Care Companion J Clin Psychiatry, 2004. 6(4): p. 159-166.
  12. Dwoskin, L.P., Preface. Emerging targets and therapeutics in the treatment of psychostimulant abuse. Adv Pharmacol, 2014. 69: p. xi-xiii.
  13. Buspirone Hydrochloride [package insert]. Patheon Pharmaceuticals Inc. Cincinnati, OH. December 2013 [cited 2015 November 03]; Available from: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3fe0ccd-565f-4d0a-a7ba-2fad7a819358.
  14. Anttila, S.A. and E.V. Leinonen, A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev, 2001. 7(3): p. 249-64.
  15. Brockmoller, J., I. Meineke, and J. Kirchheiner, Pharmacokinetics of mirtazapine: enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effects. Clin Pharmacol Ther, 2007. 81(5): p. 699-707.
  16. Greene, D.S. and R.H. Barbhaiya, Clinical pharmacokinetics of nefazodone. Clin Pharmacokinet, 1997. 33(4): p. 260-75.
  17. Choi, S., Nefazodone (Serzone) withdrawn because of hepatotoxicity. CMAJ, 2003. 169(11): p. 1187.
  18. Papakostas, G.I. and M. Fava, A meta-analysis of clinical trials comparing the serotonin (5HT)-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Eur Psychiatry, 2007. 22(7): p. 444-7.
  19. Fagiolini, A., et al., Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs, 2012. 26(12): p. 1033-49.
  20. Katona, C.L. and C.P. Katona, New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. Neuropsychiatr Dis Treat, 2014. 10: p. 349-54.
  21. Sanchez, C., K.E. Asin, and F. Artigas, Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther, 2015. 145: p. 43-57.
  22. Raskind, M.A., et al., Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology, 2000. 54(12): p. 2261-8.
  23. Tariot, P.N., et al., A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology, 2000. 54(12): p. 2269-76.
  24. Wilcock, G.K., S. Lilienfeld, and E. Gaens, Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ, 2000. 321(7274): p. 1445-9.
  25. Wilkinson, D. and J. Murray, Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer’s disease. Int J Geriatr Psychiatry, 2001. 16(9): p. 852-7.
  26. Robertson, P., et al., In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil. Drug Metab Dispos, 2000. 28(6): p. 664-71.
  27. Grozinger, M., et al., Interaction of modafinil and clomipramine as comedication in a narcoleptic patient. Clin Neuropharmacol, 1998. 21(2): p. 127-9.
  28. Hayden, M.R., et al., Tetrabenazine. Nat Rev Drug Discov, 2009. 8(1): p. 17-8.
  29. Sauer, J.M., et al., Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. Drug Metab Dispos, 2003. 31(1): p. 98-107.
  30. Goodkin, H.P. and J. Kapur, The impact of diazepam’s discovery on the treatment and understanding of status epilepticus. Epilepsia, 2009. 50(9): p. 2011-8.
  31. Stefan, H. and T.J. Feuerstein, Novel anticonvulsant drugs. Pharmacol Ther, 2007. 113(1): p. 165-83.
  32. Locharernkul, C., et al., Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia, 2008. 49(12): p. 2087-91.
  33. Hung, S.I., et al., Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics, 2010. 11(3): p. 349-56.
  34. Chateauvieux, S., et al., Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol, 2010. 2010.
  35. Stewart, J.D., et al., Polymerase gamma gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology, 2010. 52(5): p. 1791-6.
  36. He, N., et al., Cutaneous reactions induced by oxcarbazepine in Southern Han Chinese: incidence, features, risk factors and relation to HLA-B alleles. Seizure, 2012. 21(8): p. 614-8.
  37. Shear, N.H. and S.P. Spielberg, Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J Clin Invest, 1988. 82(6): p. 1826-32.
  38. Shi, Y.W., et al., Hla-B alleles and lamotrigine-induced cutaneous adverse drug reactions in the Han Chinese population. Basic Clin Pharmacol Toxicol, 2011. 109(1): p. 42-6.
  39. Tzoulis, C., et al., The spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases. Brain, 2006. 129(Pt 7): p. 1685-92.
  40. Saneto, R.P., et al., POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders. Seizure, 2010. 19(3): p. 140-6.
  41. Pronicka, E., et al., Drug-resistant epilepsia and fulminant valproate liver toxicity. Alpers-Huttenlocher syndrome in two children confirmed post mortem by identification of p.W748S mutation in POLG gene. Med Sci Monit, 2011. 17(4): p. CR203-9.
  42. Hartung, B., et al., Perphenazine for schizophrenia. Cochrane Database Syst Rev, 2005(1): p. CD003443.
  43. Thanacoody, R.H., et al., Factors affecting drug concentrations and QT interval during thioridazine therapy. Clin Pharmacol Ther, 2007. 82(5): p. 555-65.
  44. Haloperidol (Haldol) [package insert]. Ortho-McNeil-Janssen Pharmaceuticals, Inc., St. Louis, MO. June 2011 [cited 2015 October 22]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018701s054lbl.pdf.
  45. Thioridazine. DrugBank website. September 16, 2013 [cited 2015 October 22]; Available from: http://www.drugbank.ca/drugs/DB00679.
  46. Bowen, W.D., et al., Metabolites of haloperidol display preferential activity at sigma receptors compared to dopamine D-2 receptors. Eur J Pharmacol, 1990. 177(3): p. 111-8.
  47. Reimold, M., et al., Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. Psychopharmacology (Berl), 2007. 190(2): p. 241-9.
  48. Swainston Harrison, T. and C.M. Perry, Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs, 2004. 64(15): p. 1715-36.
  49. Rodriguez-Antona, C., et al., CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies. Pharmacogenomics, 2009. 10(4): p. 685-99.
  50. Oshiro, Y., et al., Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives. J Med Chem, 1998. 41(5): p. 658-67.
  51. Jordan, S., et al., The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol, 2002. 441(3): p. 137-40.
  52. Shapiro, D.A., et al., Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology, 2003. 28(8): p. 1400-11.
  53. Grunder, G., A. Carlsson, and D.F. Wong, Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry, 2003. 60(10): p. 974-7.
  54. Lieberman, J.A., Dopamine partial agonists: a new class of antipsychotic. CNS Drugs, 2004. 18(4): p. 251-67.
  55. Arranz, M.J., M. Rivera, and J.C. Munro, Pharmacogenetics of response to antipsychotics in patients with schizophrenia. CNS Drugs, 2011. 25(11): p. 933-69.
  56. Struder, H.K. and H. Weicker, Physiology and pathophysiology of the serotonergic system and its implications on mental and physical performance. Part I. Int J Sports Med, 2001. 22(7): p. 467-81.
  57. Balt, S.L., et al., Mechanisms and genetics of antipsychotic-associated weight gain. Clin Pharmacol Ther, 2011. 90(1): p. 179-83.
  58. DailyMed – https://dailymed.nlm.nih.gov/dailymed/index.cfm
  59. Zuclopenthixol. https://www.medicines.org.uk/emc/PIL.5395.latest.pdf